Clinical Trials

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

USA
California
Stanford

PURPOSE:

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced MF/SS.

ELIGIBILITY:

Ages Eligible for Study:                     18 Years and older
Genders Eligible for Study:               Both
Conditions:

Blood and Marrow Transplant; Skin Cancer; Lymphomas: Non-Hodgkin-Cutaneous Lymphoma; Sezary Syndrome; Mycoses
Health of Volunteers: People with the conditions listed in this trial can participate as controls.
 

INCLUSION CRITERIA:

  • Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1 standard systemic therapy or are not candidates for standard therapy.
  • Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center
  • Age > 18 years and <= 75 years
  • Karnofsky Performance Status >= 70%
  • Corrected DLCO >= 40%
  • Left ventricle ejection fraction (LVEF) > 30%
  • ALT and AST must be <= 3X normal. Total bilirubin <= 3 mg/dL unless hemolysis or Gilbert’s disease
  • Estimated creatinine clearance >= 50 ml/min
  • Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1
  • Signed informed consent.
     

DONOR INCLUSION CRITERIA:

  • Age >=17
  • HIV seronegative
  • Signed informed consent
  • No contraindication to the administration of G-CSF
  • Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate

EXCLUSION CRITERIA:

  • Uncontrolled active infection
  • Uncontrolled congestive heart failure or angina
  • Pregnancy or nursing patients will be excluded from the study
  • Those who are HIV-positive will be excluded from the study due to high risk of lethal infection after hematopoietic cell transplantation.
  • No prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patients has been disease-free for five years.

DONOR EXCLUSION CRITERIA:

  • Serious medical or psychological illness.
  • Pregnant or lactating women are not eligible
  • Prior malignancies within the last 5 years except for non-melanoma skin cancers

SPONSOR:

Stanford University

CLINICALTRIALS.GOV IDENTIFIER:

NCT00896493

CONTACT:

Stanford University School of Medicine
300 Pasteur Drive, Stanford, CA 94305
BMT Referrals, 650.723.0822
Principal Investigator: Youn H. Kim, M.D.

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.